Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor

Many drugs are promiscuous and bind to multiple targets. On the one hand, these targets may be linked to unwanted side effects, but on the other, they may achieve a combined desired effect (polypharmacology) or represent multiple diseases (drug repositioning). With the growth of 3D structures of dru...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2020-05, Vol.15 (5), p.e0233089
Main Authors: Adasme, Melissa F., Parisi, Daniele, Van Belle, Kristien, Salentin, Sebastian, Haupt, V. Joachim, Jennings, Gary S., Heinrich, Jörg-Christian, Herman, Jean, Sprangers, Ben, Louat, Thierry, Moreau, Yves, Schroeder, Michael
Format: Article
Language:English
Subjects:
Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors
Agammaglobulinaemia Tyrosine Kinase - metabolism
Angiogenesis
Antineoplastic agents
Autoimmune diseases
B cells
B-Lymphocytes - metabolism
Binding sites
Biology and Life Sciences
Biotechnology
Bruton's tyrosine kinase
Cancer
Cancer therapies
Cell activation
Chemotherapy
Conservation
Cytotoxicity
Deactivation
Disease
Diseases
Drug interactions
Drug Repositioning - methods
Drugs
Genes
Growth factor receptors
Growth factors
Humans
Ibrutinib
Identification and classification
Immunology
Inactivation
Inhibitor drugs
Interfaces
Jurkat Cells
Kidney cancer
Kinases
Laboratories
Lupus
Lymphocytes B
Lymphoma
Medicine and Health Sciences
Multiple myeloma
Nephrology
Pazopanib
Pharmacological research
Phenols (Class of compounds)
Promiscuity
Protein-tyrosine kinase
Pyrazoles - chemistry
Pyrazoles - pharmacology
Pyrimidines - chemistry
Pyrimidines - pharmacology
Research and Analysis Methods
Rheumatoid arthritis
RNA Interference
Side effects
Signal Transduction - drug effects
Sorafenib
Structure (Literature)
Structure-activity relationships (Pharmacology)
Sunitinib
Suramin - chemistry
Suramin - pharmacology
Target recognition
Targeted cancer therapy
Therapeutic targets
Time
Tyrosine
Vascular endothelial growth factor
Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors
Vascular Endothelial Growth Factor Receptor-2 - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!